XML 24 R6.htm IDEA: XBRL DOCUMENT v3.7.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Mar. 31, 2015
Operating Activities      
Net income $ 69,395 $ 99,907 $ 78,260
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization 25,792 23,676 17,740
Loss on divestitures and sales of property and equipment 51,820 0 0
Gain on sale of asset 0 0 (1,133)
Deferred income taxes (5,778) 46,152 28,922
Long term income taxes payable 581 (332) 2,294
Amortization of debt origination costs 8,633 8,994 8,821
Stock-based compensation costs 8,148 9,954 6,918
Stock-based compensation costs 8,148 9,954 6,918
Loss on extinguishment of debt 1,420 17,970 0
Premium payment on 2012 Senior Notes 0 (10,158) 0
Lease termination costs 524 0 785
Loss (gain) on sale or disposal of property and equipment 573 (35) 321
Changes in operating assets and liabilities, net of effects from acquisitions:      
Accounts receivable (18,938) 1,824 1,608
Inventories (10,262) (3,005) 15,360
Prepaid expenses and other assets (1,996) (7,921) 4,664
Accounts payable 21,447 (11,348) (17,637)
Accrued liabilities 2,497 (1,328) 9,332
Noncurrent assets and liabilities (6,084) 0 0
Net cash provided by operating activities 147,772 174,350 156,255
Investing Activities      
Purchases of property and equipment (2,977) (3,568) (6,101)
Proceeds from divestitures 110,717 0 18,500
Proceeds from the sale of property and equipment 85 344 0
Proceeds from sale of asset 0 0 10,000
Proceeds from Insight Pharmaceuticals working capital arbitration settlement 0 7,237 0
Proceeds from DenTek working capital arbitration settlement 1,419 0 0
Acquisition of DenTek, less cash acquired 0 (226,984) 0
Acquisition of Insight Pharmaceuticals, less cash acquired 0 0 (749,666)
Acquisition of the Hydralyte brand 0 0 (77,991)
Acquisition of C.B. Fleet, less cash acquired (803,839) 0 0
Net cash used in investing activities (694,595) (222,971) (805,258)
Financing Activities      
Proceeds from issuance of 2016 Senior Notes 0 350,000 0
Repayment of 2012 Senior Notes 0 (250,000) 0
Borrowings under Bridge term loans 0 80,000 0
Repayments under Bridge term loans 0 (80,000) 0
Proceeds from issuance of Term Loan 1,427,000 0 720,000
Term Loan repayments resulting from refinancing (687,000) 0 0
Term Loan repayments (175,500) (60,000) (130,000)
Borrowings under revolving credit agreement 110,000 115,000 124,600
Repayments under revolving credit agreement (105,000) (96,100) (58,500)
Payments of debt origination costs (11,140) (11,828) (16,072)
Proceeds from exercise of stock options 4,028 6,689 3,954
Proceeds from restricted stock exercises 0 544 57
Excess tax benefits from share-based awards 900 1,960 1,330
Fair value of shares surrendered as payment of tax withholding (1,431) (2,229) (2,104)
Net cash provided by financing activities 561,857 54,036 643,265
Effects of exchange rate changes on cash and cash equivalents (409) 497 (1,275)
Increase (decrease) in cash and cash equivalents 14,625 5,912 (7,013)
Cash and cash equivalents - beginning of year 27,230 21,318 28,331
Cash and cash equivalents - end of year 41,855 27,230 21,318
Interest paid 85,209 79,132 70,155
Income taxes paid $ 47,999 $ 15,352 $ 11,939